Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Bristol-Myers Squibb
(NY:
BMY
)
42.55
-0.81 (-1.88%)
Streaming Delayed Price
Updated: 12:23 PM EDT, May 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Bristol-Myers Squibb
< Previous
1
2
3
4
5
6
7
8
9
...
42
43
Next >
Bristol Myers' Lead Cancer Immunotherapy Shows Progression Free Survival Versus Chemo In Certain Type Of Colorectal Cancer
January 22, 2024
Bristol Myers' Opdivo + Yervoy combo shows 79% reduced risk in MSI-H/dMMR metastatic colorectal cancer.
Via
Benzinga
Ikena Oncology Refocuses on Key Programs: Analysts Maintain Outperform Ratings Amid Strategic Organizational Changes
January 19, 2024
Ikena Oncology optimizes resources for targeted oncology programs IK-930 & IK-595. Clinical updates expected H2 2024. Workforce reduced by 35%. Financially secure with $175M cash. Strategic focus on...
Via
Benzinga
Inflation-Busting Price Hikes For Ozempic, Mounjaro And Others: Are Drugmakers Profiteering?
January 18, 2024
Pharmaceuticals prices are already up in 2024: Can inflation-beating hikes be justified?
Via
Benzinga
Behind the Scenes of Bristol-Myers Squibb's Latest Options Trends
January 16, 2024
Via
Benzinga
Financial Relief For Medicare Patients: Part D Overhaul Caps Out-of-Pocket Drug Cost Limits
January 16, 2024
In 2024, the Inflation Reduction Act limits out-of-pocket drug costs to $3,300 annually, with further reductions to $2,000 in 2025.
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Decoding Bristol-Myers Squibb's Options Activity: What's the Big Picture?
January 11, 2024
Via
Benzinga
Looking Into Bristol-Myers Squibb's Recent Short Interest
January 05, 2024
Via
Benzinga
Why NYSE:BMY qualifies as a good dividend investing stock.
January 04, 2024
Balancing Dividends and Fundamentals: The Case of BRISTOL-MYERS SQUIBB CO (NYSE:BMY).
Via
Chartmill
Analyst Expectations For Bristol-Myers Squibb's Future
December 27, 2023
Via
Benzinga
Cytokinetics' Heart Drug Is A Multi-Billion Dollar Opportunity By 2032 Despite Novartis Setback: Analyst
January 12, 2024
Novartis halts pursuit of Cytokinetics acquisition, impacting promising heart drug. Analysts estimate $3.6 billion sales for Cytokinetics' cardiomyopathy drug by 2032. Still lead drug aficamten viewed...
Via
Benzinga
Why Big Pharma Led By Merck, Sanofi, Teva Are Pouring Billions Into A New Immunology Space
January 12, 2024
The companies are working on blocking TL1A, a protein tied to inflammatory bowel disease.
Via
Investor's Business Daily
Bullish Continuation In '24? 3 Market Areas To Watch
January 10, 2024
This article discusses 3 market areas that should outperform dramatically over the next 12 months...
Via
Talk Markets
5 Biotech Stocks That Should Be On Investors' Radar As JPMorgan Healthcare Conference Gets Underway Monday
January 08, 2024
The rebound by biopharma stocks in 2023 and the pickup in M&A news flow makes the 2024 JPMorgan Healthcare conference even more interesting.
Via
Benzinga
3 Magnificent High-Yield Dividend Stocks to Buy in 2024
January 06, 2024
There's more than meets the eye with all three of these dividend stocks.
Via
The Motley Fool
Strides Toward Lower Drug Costs: Florida Becomes First To Receive Nod To Import Prescription Drugs from Canada
January 05, 2024
The FDA has allowed Florida to import prescription drugs from Canada, potentially altering the landscape of how Americans access and afford their medications.
Via
Benzinga
Exposures
Product Safety
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
January 05, 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.
Via
Investor's Business Daily
3 Dividend Stocks for Strong Returns in 2024 and Beyond
January 04, 2024
Investors should consider these three dividend stocks for 2024 and beyond, as they offer compelling yields and safety.
Via
InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
January 04, 2024
Via
Benzinga
7 Stocks Primed for a Spectacular Comeback in 2024
January 03, 2024
Although the usual suspects may carry confidence, these underappreciated comeback stocks might deliver the goods in 2024.
Via
InvestorPlace
This Analyst Downgrades Bristol-Myers Squibb, Cautions Amid Product Launch And Revenue Concerns
January 03, 2024
BofA Securities downgraded Bristol-Myers Squibb & Co (NYSE: BMY), noting that initially, the analyst believed that Bristol's loss of exclusivity (LOEs) for drugs like Eliquis and Opdivo was widely...
Via
Benzinga
3 Strong Dividend Stocks to Buy Early On in 2024
January 03, 2024
The markets are always looking forward, and you should, too. Here are three dividend stocks to buy now.
Via
The Motley Fool
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
December 29, 2023
Each week, Benzinga's Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface and warrant attention.
Via
Benzinga
Stock Market Ending 2023 On High Note; Tesla, Drug M&A In Focus: Weekly Review
December 29, 2023
The major indexes boast big annual gains with the Dow at record highs.
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024
December 29, 2023
According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2023.
Via
Benzinga
Cytokinetics' Drug Potential: Analyst Suggests Key Role Of Established Pharma For Potential Launch
December 28, 2023
On Wednesday, Cytokinetics Incorporated (NASDAQ: CYTK) released topline results from the SEQUOIA-HCM Phase 3 trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy...
Via
Benzinga
Pharmaceutical Giants Brace for Showdown as Medicare Drug Price Negotiations Are Poised For 2024
December 28, 2023
2024 will mark a pivotal moment for the healthcare industry, particularly in drug pricing negotiations.
Via
Benzinga
Why Is Blood Purification Focused CytoSorbents Trading Lower Today?
December 28, 2023
CytoSorbents Corporation (NASDAQ: CTSO) released an update on the initial data analysis of primary safety and effectiveness endpoints and the final independent Data and Safety Monitoring Board for the...
Via
Benzinga
Why Is Cytokinetics (CYTK) Stock Up 70% Today?
December 27, 2023
With Cytokinetics hitting a homerun with its heart failure drug, CYTK stock skyrocketed in part due to takeover interest.
Via
InvestorPlace
Recent M&A Bodes Well For Targeted Cancer Therapy Player Fusion Pharmaceuticals, Analyst Say AstraZeneca Is Favorably Positioned
December 27, 2023
With recent merger and acquisition deals in the targeted radiopharmaceutical therapy (TRT) space, on Tuesday, Oppenheimer noted that Fusion Pharmaceuticals Inc (NASDAQ: FUSN) is potentially the sole...
Via
Benzinga
Meta To Rally Over 18%? Here Are 10 Top Analyst Forecasts For Wednesday
December 27, 2023
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
42
43
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.